| Literature DB >> 32576224 |
Xiaoyang Wang1, Chenbin Liu2, Liang Hong3, Cuiyun Yuan2, Jiguang Ding3, Qing Jia1, Gangqiang Sun4, Wenxian Peng5, Qingfeng Sun6.
Abstract
BACKGROUND: We aimed to describe the chest CT findings in sixty-seven patients infected by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).Entities:
Keywords: COVID-19; CT imaging; SARS-CoV-2
Mesh:
Year: 2020 PMID: 32576224 PMCID: PMC7309204 DOI: 10.1186/s12880-020-00471-6
Source DB: PubMed Journal: BMC Med Imaging ISSN: 1471-2342 Impact factor: 1.930
Demographic and clinical characteristics of 67 patients with SARS-CoV-2
| Number | |
|---|---|
| Gender (male) | 31 (46.3%) |
| Positive CT findings | 56 (83.6%) |
| Age | 44 (5 ~ 72) |
| Job type | 4 (6.0%) farmers, 59 (88.0%) self-employed, 4 (6.0%) company employees |
| Infection source type | 34 (50.8%) lived in Wuhan, 3 (4.4%) lived in Hubei Province, 27 (40.3%) got contact with patients, 2 (3.0%) got contact with suspected patient, 1 (1.5%) unknown |
| Smoking status | 62 (92.5%) are non-smokers, 2 (3.0%) are former smokers, 3 (4.5%) are current smokers |
| Severe patients | 3 (4.5%) |
| Fever | 58 (86.6%) |
| Cough | 52 (77.6%) |
| Sputum production | 35 (52.2%) |
| Chest tightness | 12 (17.9%) |
| Sore throat | 8 (11.9%) |
| Diarrhea | 5 (7.5%) |
| Dizziness | 3 (4.5%) |
| Shortness of breath | 4 (6.0%) |
| Nausea and vomiting | 2 (3.0%) |
| Myalgia or fatigue | 3 (4.5%) |
| Headache | 2 (3.0%) |
Current status (cured/hospitalized) | 44 (65.7%) cured, 23 (34.3%) hospitalized |
CT features in sixty-seven patients with SARS-CoV-2
| Number | |
|---|---|
| Peripheral/central lesions | 50 (92.6%) peripheral; 4 (7.4%) central |
| Lesions in middle upper/lower lobes | 12 (22.2%) upper lobe; 42 (77.8%) lower lobe |
| Single/multiple lesions | 8 (14.8%) single; 46 (85.2%) multiple |
| Ground-glass opacities | 42 (77.8%) |
| Consolidation | 12 (22.2%) |
| Interlobular septal thickening | 11 (20.4%) |
| Reversed halo sign | 9 (16.7%) |
| Air bronchogram | 18 (33.3%) |
| Bronchial wall thickening | 3 (5.6%) |
| Tree-in-bud pattern | 1 (1.9%) |
| Air cavity | 4 (7.4%) |
| Pleural thickening or pleural effusion | 14 (25.9%) |
| Intrathoracic lymph node enlargement | 2 (3.7%) |
Fig. 1A male patient infected with SARS-CoV-2 who presented severe difficulty in breathing. Transverse CT performed on six days after onset of symptoms shows peripheral ground glass opacities (red arrow) under the pleura of the middle and lower lobes in both lungs
Fig. 2A male patient infected with SARS-CoV-2. a The first CT was performed three days after the onset of symptoms. The chest CT image shows single consolidation in the right middle lobe and air bronchogram (red arrows). b The second CT was performed 13 days after the treatment. The chest CT image shows a tree-in-bud pattern (white arrows)
Fig. 3A male patient infected with SARS-CoV-2. a The first CT was performed three days after the onset of symptoms. The chest CT image shows ground glass opacities in the lower lobe and air cavities (red arrows). b The second CT was performed three days after the treatment. The chest CT image shows ground glass opacities occupying the left lower lobe (blue arrow)
Fig. 4A female patient infected with SARS-CoV-2. The first CT scans (a) and (c) were performed four days after onset of symptoms. The second CT scans (b) and (d) were performed ten days after the treatment. Chest CT images showed the enlargement of ground glass opacity (red arrows) and intrathoracic lymph node (blue arrows) after 10-day treatment
Fig. 5A male patient infected with SARS-CoV-2. a The first CT was performed three days after the onset of symptoms. The chest CT image shows a tree-in-bud pattern (red arrow). b The second CT was performed two weeks after the treatment. The chest CT image shows the tree-in-bud pattern was fully absorbed after the treatment